Novo Nordisk A/S (NVO) EV/EBITDA Ratio: 7.34x
Is Novo Nordisk A/S’s EV/EBITDA ratio high or low?
Novo Nordisk A/S's EV/EBITDA ratio of 7.34x is 68% below its 5-year average of 22.78x, near the low end of its 5-year range (6.94x–36.49x).
As of Thursday, June 18, 2026. 22.74% below its 12-month average of 9.50x.
NVO EV/EBITDA Ratio Chart
NVO Average EV/EBITDA Ratio Chart
NVO Current vs Average EV/EBITDA Ratio Chart
NVO EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
7.34x
EV/EBITDA RATIO AVG TTM
9.50x
EV/EBITDA RATIO AVG 3Y
21.24x
EV/EBITDA RATIO AVG 5Y
22.78x
EV/EBITDA RATIO AVG 10Y
19.15x
EV/EBITDA RATIO AVG 15Y
17.39x
EV/EBITDA RATIO AVG 20Y
16.96x
CURRENT VS TTM AVG
-22.74%
CURRENT VS 3Y AVG
-65.44%
CURRENT VS 5Y AVG
-67.78%
CURRENT VS 10Y AVG
-61.66%
CURRENT VS 15Y AVG
-57.79%
CURRENT VS 20Y AVG
-56.71%
NVO Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $191.59B | 7.34x | 9.50x | 21.24x | 22.78x |
| Amgen Inc. (AMGN)vs › | $184.40B | 13.85x | 13.60x | 14.33x | 14.03x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $171.57B | 19.01x | 19.80x | 20.45x | 20.33x |
| Gilead Sciences, Inc. (GILD)vs › | $155.75B | 12.26x | 14.06x | 17.97x | 15.90x |
| Abbott Laboratories (ABT)vs › | $154.08B | 16.22x | 18.54x | 19.26x | 18.55x |
| Pfizer Inc. (PFE)vs › | $147.73B | 12.62x | 10.57x | 15.99x | 13.73x |
| Intuitive Surgical, Inc. (ISRG)vs › | $142.44B | 33.03x | 46.78x | 54.22x | 52.24x |
| CVS Health Corporation (CVS)vs › | $126.52B | 17.57x | 15.02x | 11.90x | 12.02x |
| Danaher Corporation (DHR)vs › | $125.88B | 20.95x | 23.46x | 23.91x | 22.36x |
| Stryker Corporation (SYK)vs › | $119.03B | 20.89x | 30.76x | 30.61x | 30.60x |
EV/EBITDA vs. its own history
At 7.3, EV/EBITDA is cheaper than usual, sitting higher than 0% of its 20-year history.
20-year low
6.9
median
17.3
20-year high
36.5
Novo Nordisk A/S EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The EV/EBITDA ratio for NVO stock is 7.34x.
- Is Novo Nordisk A/S's EV/EBITDA ratio high or low?
- Novo Nordisk A/S's EV/EBITDA ratio of 7.34x is 68% below its 5-year average of 22.78x, near the low end of its 5-year range (6.94x–36.49x).
- What is the TTM average EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The TTM average EV/EBITDA ratio for NVO stock is 9.50x.
- What is the 3Y average EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The 3Y average EV/EBITDA ratio for NVO stock is 21.24x.
- What is the 5Y average EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The 5Y average EV/EBITDA ratio for NVO stock is 22.78x.
- What is the 10Y average EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The 10Y average EV/EBITDA ratio for NVO stock is 19.15x.
- What is the 15Y average EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The 15Y average EV/EBITDA ratio for NVO stock is 17.39x.
- What is the 20Y average EV/EBITDA ratio for Novo Nordisk A/S (NVO)?
- The 20Y average EV/EBITDA ratio for NVO stock is 16.96x.
Novo Nordisk A/S EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-17 | 7.34x |
| 2026-06-16 | 7.35x |
| 2026-06-15 | 7.41x |
| 2026-06-12 | 7.40x |
| 2026-06-11 | 7.41x |
| 2026-06-10 | 7.23x |
| 2026-06-09 | 7.14x |
| 2026-06-08 | 6.96x |
| 2026-06-05 | 7.26x |
| 2026-06-04 | 7.38x |
| 2026-06-03 | 7.11x |
| 2026-06-02 | 7.25x |
| 2026-06-01 | 7.43x |
| 2026-05-29 | 7.66x |
| 2026-05-28 | 7.65x |
| 2026-05-27 | 7.50x |
| 2026-05-26 | 7.45x |
| 2026-05-22 | 7.56x |
| 2026-05-21 | 7.48x |
| 2026-05-20 | 7.58x |
| 2026-05-19 | 7.46x |
| 2026-05-18 | 7.46x |
| 2026-05-15 | 7.53x |
| 2026-05-14 | 7.69x |
| 2026-05-13 | 7.89x |
| 2026-05-12 | 7.88x |
| 2026-05-11 | 7.79x |
| 2026-05-08 | 7.74x |
| 2026-05-07 | 7.69x |
| 2026-05-06 | 7.69x |
| 2026-05-05 | 8.64x |
| 2026-05-04 | 8.56x |
| 2026-05-01 | 8.46x |
| 2026-04-30 | 8.17x |
| 2026-04-29 | 7.83x |
| 2026-04-28 | 7.98x |
| 2026-04-27 | 7.99x |
| 2026-04-24 | 7.98x |
| 2026-04-23 | 7.51x |
| 2026-04-22 | 7.62x |
| 2026-04-21 | 7.67x |
| 2026-04-20 | 7.86x |
| 2026-04-17 | 7.87x |
| 2026-04-16 | 7.94x |
| 2026-04-15 | 7.92x |
| 2026-04-14 | 7.65x |
| 2026-04-13 | 7.41x |
| 2026-04-10 | 7.33x |
| 2026-04-09 | 7.32x |
| 2026-04-08 | 7.35x |
| 2026-04-07 | 7.22x |
| 2026-04-06 | 7.18x |
| 2026-04-02 | 7.24x |
| 2026-04-01 | 7.15x |
| 2026-03-31 | 7.20x |
| 2026-03-30 | 6.94x |
| 2026-03-27 | 7.07x |
| 2026-03-26 | 7.13x |
| 2026-03-25 | 7.12x |
| 2026-03-24 | 7.22x |
| 2026-03-23 | 7.21x |
| 2026-03-20 | 7.16x |
| 2026-03-19 | 7.25x |
| 2026-03-18 | 7.32x |
| 2026-03-17 | 7.50x |
| 2026-03-16 | 7.52x |
| 2026-03-13 | 7.41x |
| 2026-03-12 | 7.42x |
| 2026-03-11 | 7.57x |
| 2026-03-10 | 7.55x |
| 2026-03-09 | 7.74x |
| 2026-03-06 | 7.52x |
| 2026-03-05 | 7.61x |
| 2026-03-04 | 7.51x |
| 2026-03-03 | 7.18x |
| 2026-03-02 | 7.38x |
| 2026-02-27 | 7.32x |
| 2026-02-26 | 7.35x |
| 2026-02-25 | 7.45x |
| 2026-02-24 | 7.52x |
| 2026-02-23 | 7.71x |
| 2026-02-20 | 9.09x |
| 2026-02-19 | 9.28x |
| 2026-02-18 | 9.42x |
| 2026-02-17 | 9.44x |
| 2026-02-13 | 9.48x |
| 2026-02-12 | 9.36x |
| 2026-02-11 | 9.33x |
| 2026-02-10 | 9.40x |
| 2026-02-09 | 9.44x |
| 2026-02-06 | 9.13x |
| 2026-02-05 | 8.37x |
| 2026-02-04 | 9.05x |
| 2026-02-03 | 9.61x |
| 2026-02-02 | 10.87x |
| 2026-01-30 | 10.96x |
| 2026-01-29 | 10.94x |
| 2026-01-28 | 11.12x |
| 2026-01-27 | 11.57x |
| 2026-01-26 | 11.77x |
| 2026-01-23 | 11.46x |
| 2026-01-22 | 11.46x |
| 2026-01-21 | 10.94x |
| 2026-01-20 | 11.18x |
| 2026-01-16 | 11.47x |
| 2026-01-15 | 10.55x |
| 2026-01-14 | 10.87x |
| 2026-01-13 | 11.00x |
| 2026-01-12 | 11.04x |
| 2026-01-09 | 10.85x |
| 2026-01-08 | 10.59x |
| 2026-01-07 | 10.45x |
| 2026-01-06 | 10.40x |
| 2026-01-05 | 10.19x |
| 2026-01-02 | 9.71x |
| 2025-12-31 | 9.44x |
| 2025-12-30 | 9.51x |
| 2025-12-29 | 9.55x |
| 2025-12-26 | 9.71x |
| 2025-12-24 | 9.74x |
| 2025-12-23 | 9.57x |
| 2025-12-22 | 8.95x |
| 2025-12-19 | 8.95x |
| 2025-12-18 | 8.87x |
| 2025-12-17 | 8.89x |
| 2025-12-16 | 9.10x |
| 2025-12-15 | 9.35x |
| 2025-12-12 | 9.32x |
| 2025-12-11 | 9.34x |
| 2025-12-10 | 9.12x |
| 2025-12-09 | 8.64x |
| 2025-12-08 | 8.72x |
| 2025-12-05 | 8.91x |
| 2025-12-04 | 8.93x |
| 2025-12-03 | 8.86x |
| 2025-12-02 | 8.83x |
| 2025-12-01 | 9.01x |
| 2025-11-28 | 9.17x |
| 2025-11-26 | 9.06x |
| 2025-11-25 | 8.77x |
| 2025-11-24 | 8.40x |
| 2025-11-21 | 8.87x |
| 2025-11-20 | 8.86x |
| 2025-11-19 | 9.11x |
| 2025-11-18 | 8.86x |
| 2025-11-17 | 9.02x |
| 2025-11-14 | 8.98x |
| 2025-11-13 | 9.14x |
| 2025-11-12 | 9.34x |
| 2025-11-11 | 9.14x |
| 2025-11-10 | 8.57x |
| 2025-11-07 | 8.52x |
| 2025-11-06 | 8.67x |
| 2025-11-05 | 9.02x |
| 2025-11-04 | 8.93x |
| 2025-11-03 | 9.08x |
| 2025-10-31 | 9.14x |
| 2025-10-30 | 9.24x |
| 2025-10-29 | 9.47x |
| 2025-10-28 | 9.59x |
| 2025-10-27 | 9.74x |
| 2025-10-24 | 9.75x |
| 2025-10-23 | 9.80x |
| 2025-10-22 | 9.82x |
| 2025-10-21 | 10.07x |
| 2025-10-20 | 10.24x |
| 2025-10-17 | 10.00x |
| 2025-10-16 | 10.30x |
| 2025-10-15 | 10.41x |
| 2025-10-14 | 10.40x |
| 2025-10-13 | 10.54x |
| 2025-10-10 | 10.44x |
| 2025-10-09 | 10.75x |
| 2025-10-08 | 10.91x |
| 2025-10-07 | 10.81x |
| 2025-10-06 | 10.92x |
| 2025-10-03 | 10.92x |
| 2025-10-02 | 10.76x |
| 2025-10-01 | 10.83x |
| 2025-09-30 | 10.19x |
| 2025-09-29 | 10.19x |
| 2025-09-26 | 10.21x |
| 2025-09-25 | 10.29x |
| 2025-09-24 | 10.76x |
| 2025-09-23 | 10.90x |
| 2025-09-22 | 11.10x |
| 2025-09-19 | 11.22x |
| 2025-09-18 | 11.30x |
| 2025-09-17 | 10.67x |
| 2025-09-16 | 10.49x |
| 2025-09-15 | 10.21x |
| 2025-09-12 | 10.08x |
| 2025-09-11 | 9.98x |
| 2025-09-10 | 10.00x |
| 2025-09-09 | 9.98x |
| 2025-09-08 | 9.98x |
| 2025-09-05 | 10.15x |
| 2025-09-04 | 10.31x |
| 2025-09-03 | 10.41x |
| 2025-09-02 | 10.35x |
| 2025-08-29 | 10.36x |
| 2025-08-28 | 10.30x |
| 2025-08-27 | 10.36x |
| 2025-08-26 | 10.17x |
| 2025-08-25 | 10.34x |
| 2025-08-22 | 10.45x |
| 2025-08-21 | 10.19x |
| 2025-08-20 | 9.98x |
| 2025-08-19 | 10.07x |
| 2025-08-18 | 9.89x |
| 2025-08-15 | 9.65x |
| 2025-08-14 | 9.40x |
| 2025-08-13 | 9.39x |
| 2025-08-12 | 9.19x |
| 2025-08-11 | 9.21x |
| 2025-08-08 | 9.42x |
| 2025-08-07 | 9.02x |
| 2025-08-06 | 8.43x |
| 2025-08-05 | 9.33x |
| 2025-08-04 | 9.63x |
| 2025-08-01 | 9.51x |
| 2025-07-31 | 9.30x |
| 2025-07-30 | 9.86x |
| 2025-07-29 | 10.59x |
| 2025-07-28 | 13.41x |
| 2025-07-25 | 13.92x |
| 2025-07-24 | 13.74x |
| 2025-07-23 | 13.60x |
| 2025-07-22 | 13.00x |
| 2025-07-21 | 12.65x |
| 2025-07-18 | 12.53x |
| 2025-07-17 | 12.72x |
| 2025-07-16 | 13.04x |
| 2025-07-15 | 13.08x |
| 2025-07-14 | 13.40x |
| 2025-07-11 | 13.40x |
| 2025-07-10 | 13.79x |
| 2025-07-09 | 13.54x |
| 2025-07-08 | 13.53x |
| 2025-07-07 | 13.47x |
| 2025-07-03 | 13.44x |
| 2025-07-02 | 13.57x |
| 2025-07-01 | 13.57x |
| 2025-06-30 | 13.42x |
| 2025-06-27 | 13.32x |
| 2025-06-26 | 13.17x |
| 2025-06-25 | 13.10x |
| 2025-06-24 | 13.74x |
| 2025-06-23 | 13.55x |
| 2025-06-20 | 14.31x |
| 2025-06-18 | 14.35x |
| 2025-06-17 | 14.41x |
| 2025-06-16 | 14.91x |
| 2025-06-13 | 15.44x |
| 2025-06-12 | 15.67x |
| 2025-06-11 | 15.23x |
| 2025-06-10 | 15.35x |
| 2025-06-09 | 14.62x |
| 2025-06-06 | 14.47x |
| 2025-06-05 | 14.10x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar